BioCardia (BCDA) CFO awarded 41,501 options; shares withheld for tax
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
BioCardia, Inc. Chief Financial Officer David McClung reported routine equity compensation and related tax withholding transactions. He received a grant of 41,501 stock options, each giving the right to buy common stock at $1.20 per share. The option vests in equal monthly installments over 48 months starting on August 6, 2026, and expires on July 6, 2036.
Separately, 23,125 shares of common stock were withheld by BioCardia at $1.24 per share to cover income tax obligations from restricted stock units that vested on June 29, 2026. The footnote specifies this withholding does not represent an open-market sale by McClung. After these transactions, he holds 114,245 common shares and 87,841 stock options directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
McClung David
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (right to buy) | 41,501 | $0.00 | -- |
| Tax Withholding | Common Stock | 23,125 | $1.24 | $29K |
Holdings After Transaction:
Stock Option (right to buy) — 87,841 shares (Direct, null);
Common Stock — 114,245 shares (Direct, null)
Footnotes (1)
- The reported securities represent the shares that have been withheld by the Issuer to satisfy its income tax, withholding and remittance obligations in connection with the net settlement on July 2, 2026, of the RSUs vested on June 29, 2026 and does not represent a sale by the Reporting Person. The option vests and becomes exercisable as to 1/48th of the shares on August 6, 2026, and each month thereafter, subject to the Reporting Person continuing as a service provider through such date.
Key Figures
Option grant size: 41,501 options
Option exercise price: $1.20 per share
Option expiration: July 6, 2036
+4 more
7 metrics
Option grant size
41,501 options
Stock option grant to CFO on July 6, 2026
Option exercise price
$1.20 per share
Exercise price of newly granted options
Option expiration
July 6, 2036
Expiration date of granted stock options
Shares withheld for tax
23,125 shares
Common shares withheld to satisfy tax obligations at $1.24
Withholding price
$1.24 per share
Value used for tax-withholding disposition of common stock
Common shares held
114,245 shares
Direct common stock holdings after transactions
Options held after grant
87,841 options
Total direct stock options following the grant
Key Terms
Restricted Stock Units, net settlement, stock option, income tax, withholding and remittance obligations
4 terms
Restricted Stock Units financial
"RSUs vested on June 29, 2026 and does not represent a sale"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
net settlement financial
"in connection with the net settlement on July 2, 2026, of the RSUs"
stock option financial
"The option vests and becomes exercisable as to 1/48th of the shares"
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
income tax, withholding and remittance obligations financial
"withheld by the Issuer to satisfy its income tax, withholding and remittance obligations"
FAQ
What did BioCardia (BCDA) CFO David McClung report in this Form 4?
BioCardia CFO David McClung reported a grant of 41,501 stock options and related tax withholding. The options allow him to buy common shares at $1.20 and vest monthly over four years, while shares were withheld to cover taxes on vested RSUs.
How many BioCardia stock options were granted to the CFO and at what price?
David McClung was granted 41,501 stock options with an exercise price of $1.20 per share. These options vest in 48 equal monthly installments starting August 6, 2026, and give him the right to purchase BioCardia common stock before the 2036 expiration.
What are David McClung’s BioCardia holdings after these Form 4 transactions?
After the reported transactions, David McClung holds 114,245 shares of BioCardia common stock directly. He also holds 87,841 stock options, including the newly granted 41,501 options that vest monthly and expire on July 6, 2036.
How do the newly granted BioCardia options to the CFO vest over time?
The 41,501 BioCardia stock options granted to CFO David McClung vest as to 1/48th of the shares each month. Vesting begins on August 6, 2026, and continues monthly thereafter, conditioned on his continued service to the company through each vesting date.